Patents by Inventor Yasuyuki Igarashi

Yasuyuki Igarashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Trimethylsphingosine derivatives
    Patent number: 6031135
    Abstract: The invention relates to trimethylsphingosine derivatives which have some or all of the activities of the parent compound.
    Type: Grant
    Filed: May 13, 1996
    Date of Patent: February 29, 2000
    Assignee: Oncomembrane, Inc.
    Inventors: Fuqiang Ruan, Yasuyuki Igarashi, Sen-Itiroh Hakomori
  • Method for inhibition of cell motility by sphingosine-1-phosphate and its derivatives
    Patent number: 5877167
    Abstract: A method of inhibiting tumor cell chemotactic motility and/or chemoinvasion, a method of inhibiting phagokinetic activity of tumor cells and neutrophils, a method of inhibiting tumor cell metastasis and a method of inhibiting inflammation due to motility and invasion into blood vessel walls of neutrophils comprising contacting the cells or administering to a host in need of treatment an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent. A method of preparing sphingosine-1-phosphate and its derivatives is also described.
    Type: Grant
    Filed: February 12, 1997
    Date of Patent: March 2, 1999
    Assignee: Otsuka America Pharmaceutical, Inc.
    Inventors: Yasuyuki Igarashi, Fugiang Ruan, Yoshito Sadahira, Shigeyuki Kawa, Sen-itiroh Hakomori
  • Plasmalopsychosines and plasmalocerebrosides
    Patent number: 5827830
    Abstract: An isolated plasmalopsychosine selected from the group consisting of compound A and compound B: ##STR1## wherein n1 is 0-50 or an isolated synthetic plasmalocerebroside selected from the group consisting of compound C and compound D: ##STR2## wherein n2 and n3 each is 0-50.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: October 27, 1998
    Assignee: The Biomembrane Intstitute
    Inventors: Edward Nudelman, Sen-Itiroh Hakomori, Steven B. Levery, Yasuyuki Igarashi, Khalid Sadozai
  • Plasmalopsychosines and plasmalocerebrosides
    Patent number: 5693620
    Abstract: An isolated plasmalopsychosine selected from the group consisting of compound A and compound B: ##STR1## wherein n1 is 0-50 or an isolated synthetic plasmalocerebroside selected from the group consisting of compound C and compound D: ##STR2## wherein n2 and n3 each is 0-50.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: December 2, 1997
    Assignee: Oncomembrane, Inc.
    Inventors: Edward Nudelman, Sen-Itiroh Hakomori, Steven B. Levery, Yasuyuki Igarashi, Khalid Sadozai
  • Method for quantifying sphingosine and for diagnosing platelet activation
    Patent number: 5677189
    Abstract: A method of detecting sphingosines and platelet activation is disclosed.
    Type: Grant
    Filed: June 29, 1995
    Date of Patent: October 14, 1997
    Assignee: Oncomembrane, Inc.
    Inventors: Yasuyuki Igarashi, Yutaka Yatomi, Hideki Ohta, Sen-Itiroh Hakomori
  • Sphingosine-1-phosphate essentially free of L-threo isomer
    Patent number: 5663404
    Abstract: A method of inhibiting tumor cell chemotactic and/or chemoinvasion motility comprising contacting the tumor cell with an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting phagokinetic activity of tumor cells and neutrophils comprising contacting the cells with a phagokinetic inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting tumor cell metastasis comprising administering to a host in need of treatment a metastasis inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent.
    Type: Grant
    Filed: January 12, 1995
    Date of Patent: September 2, 1997
    Assignee: Oncomembrane
    Inventors: Yasuyuki Igarashi, Fuqiang Ruan, Yoshito Sadahira, Shigeyuki Kawa, Sen-itiroh Hakomori
  • Sphingosine-1-phosphate/trimethylsphingosine composition
    Patent number: 5627171
    Abstract: Sphingosine-1-phosphate/N,N,N-trimethylsphingosine composition to modulate cell growth.
    Type: Grant
    Filed: April 11, 1994
    Date of Patent: May 6, 1997
    Assignee: Oncomembrane, Inc.
    Inventors: Yong S. Park, Yasuyuki Igarashi, Sen-itiroh Hakomori
  • Methylsphingosine used to treat apoptosis
    Patent number: 5583160
    Abstract: N-methylated sphingosine used to induce apoptosis.
    Type: Grant
    Filed: December 14, 1994
    Date of Patent: December 10, 1996
    Assignee: The Biomembrane Institute
    Inventors: Yasuyuki Igarashi, Sen-Itiroh Hakomori
  • Liposomal trimethylsphingosine
    Patent number: 5466716
    Abstract: Liposomal N,N,N-Trimethylsphingosine and pharmaceutical compositions comprising same.
    Type: Grant
    Filed: April 1, 1994
    Date of Patent: November 14, 1995
    Assignee: The Biomembrane Institute
    Inventors: Yasuyuki Igarashi, Mohammad N. Ahmad, Hirofumi Okoshi, Sen-itroh Hakomori
  • Method for inhibition of cell motility by sphingosine-1-phosphate, its derivatives and mimetics and method of synthesizing sphingosine-1-phosphate and its derivatives
    Patent number: 5391800
    Abstract: A method of inhibiting tumor cell chemotactic and/or chemoinvasion motility comprising contacting the tumor cell with an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting phagokinetic activity of tumor cells and neutrophils comprising contacting the cells with a phagokinetic inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting tumor cell metastasis comprising administering to a host in need of treatment a metastasis inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent.
    Type: Grant
    Filed: August 9, 1993
    Date of Patent: February 21, 1995
    Assignee: The Biomembrane Institute
    Inventors: Yasuyuki Igarashi, Fuqiang Ruan, Yoshito Sadahira, Shigeyuki Kawa, Sen-itiroh Hakomori
  • Effect of N,N,N-trimethylsphingosine on protein kinase-C activity; melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
    Patent number: 5331014
    Abstract: The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors) and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, and modulating cell adhesion molecule expression and function using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.
    Type: Grant
    Filed: June 30, 1993
    Date of Patent: July 19, 1994
    Assignee: The Biomembrane Institute
    Inventors: Satoshi Kimura, Yasuyuki Igarashi, Sen-itiroh Hakomori, Mohammad N. Ahmad, Hirofumi Okoshi, Kazuko Handa
  • Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
    Patent number: 5260288
    Abstract: A method of inhibiting tumor cell chemotactic and/or chemoinvasion motility comprising contacting the tumor cell with an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting phagokinetic activity of tumor cells and neutrophils comprising contacting the cells with a phagokinetic inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting tumor cell metastasis comprising administering to a host in need of treatment a metastasis inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent.
    Type: Grant
    Filed: April 3, 1992
    Date of Patent: November 9, 1993
    Assignee: The Biomembrane Institute
    Inventors: Yasuyuki Igarashi, Fugiang Ruan, Yoshito Sadahira, Shigeyuki Kawa, Sen-itiroh Hakomori
  • Method of preparing N,N,N-trimethylsphingosine
    Patent number: 5248824
    Abstract: The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors), and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.
    Type: Grant
    Filed: May 7, 1992
    Date of Patent: September 28, 1993
    Assignee: The Biomembrane Institute
    Inventors: Yasuyuki Igarashi, Mahammad N. Ahmad, Hirofumi Okoshi, Sen-Itiroh Hakomori
  • Effect of N,N,N-trimethylsphingosine on protein kinase-C activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
    Patent number: 5151360
    Abstract: The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors) and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, and modulating cell adhesion molecule expression and function using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory an anti-metastatic activity over related compounds.
    Type: Grant
    Filed: July 2, 1991
    Date of Patent: September 29, 1992
    Assignee: Biomembrane Institute
    Inventors: Kazuko Handa, Yasuyuki Igarashi, Mahammad N. Ahmad, Sen-Itiroh Hakomori
  • Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
    Patent number: 5137919
    Abstract: The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors), and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.
    Type: Grant
    Filed: December 31, 1990
    Date of Patent: August 11, 1992
    Assignee: Biomembrane Institute
    Inventors: Yasuyuki Igarashi, Mahammad N. Ahmad, Hirofumi Okoshi, Sen-Itiroh Hakomori